Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963461 | 0.82 | RIPK1 (0.39) | KIF11SLC6A4SLC6A2SLC6A3MEN1 | |
| SCHEMBL4078067 | 0.81 | GRM5 (0.41) | KIF11 | |
| SCHEMBL592654 | 0.76 | CA4 (0.44) | MAPTHTTRAB9A | |
| SCHEMBL360859 | 0.76 | LTA4H (0.48) | NISCHRAB9A | |
| SCHEMBL145647 | 0.76 | KIF11 (0.54) | NOTUMKIF11MEN1KMT2A | |
| SCHEMBL4293777 | 0.75 | SLC6A4 (0.42) | KIF11MAPTEPHX2GPR3SLC6A4 | |
| SCHEMBL28433765 | 0.75 | METAP2 (0.36) | NOTUMKIF11ACP1SERPINE1MAPT | |
| SCHEMBL3540667 | 0.75 | GPR3 (0.45) | NOTUMKIF11NISCHSCN5AMAPT | |
| SCHEMBL306823 | 0.74 | KIF11 (0.50) | KIF11NISCHSCN5AACP1SERPINE1 | |
| SCHEMBL18293362 | 0.74 | KIF11 (0.50) | KIF11NISCHSCN5AACP1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | claimed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | claimed |
| CN-111406059-B | Europium complexes | 东曹株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-109476629-B | Urea and thiourea substituted bicyclic derivatives as pesticides | 先正达参股股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-10988494-B2 | Europium complex | TOSOH CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200354389-A1 | EUROPIUM COMPLEX | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2020-11-12 | — | — | US | disclosed |
| CN-111406059-A | Europium complexes | 东曹株式会社 | 2020-07-10 | — | — | CN | disclosed |
| US-7595315-B2 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1716126-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1418916-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003018022-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1051394-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037607-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | NOTUM 3753/4885KIF11 2227/4885NISCH 2337/4885 |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | NOTUM 2373/4885KIF11 3129/4885NISCH 87/4885 |
| US-10988494-B2 | Europium complex | SSB, XPA, UACA | NOTUM 3538/4885KIF11 2421/4885NISCH 4522/4885 |
| US-20200354389-A1 | EUROPIUM COMPLEX | SSB, XPA, UACA | NOTUM 3538/4885KIF11 2421/4885NISCH 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.